Joseph Tucker, CEO and director at Enveric Biosciences, a biotech firm, suggested a pair of obstacles this study simply couldn’t overcome. “The thematic challenges that came to light in the…
Read More
Dr. Joseph Tucker, CEO of Enveric Biosciences, provided a broader perspective on the challenges highlighted by the FDA’s decision. “The thematic challenges that came to light in the Lykos Adcomm…
Read More
Enveric Biosciences, a forward-thinking biotechnology company specializing in neuroplastogenic treatments for neuropsychiatric disorders, has announced preclinical results that underscore the potential of their novel drug candidate, EB-003. These findings, detailed…
Read More
Psychedelics biotech Enveric Biosciences announced positive preclinical results of its EB-003 drug candidate to be delivered via oral administration. EB-003 is a new, neuroplastogenic molecule designed to treat serious mental…
Read More
Biotechnology company Enveric Biosciences (NASDAQ: ENVB) said it is prioritizing the development of EB-003, a compound designed to treat mental health disorders without hallucinogenic effects. The company said EB-003 is intended…
Read More
This past week, an FDA advisory committee voted 9-2 to reject the validity of therapy-assisted MDMA clinical trials conducted by Lykos Therapeutics for the treatment of PTSD. The FDA does…
Read More
A day after a panel of advisers to the Food and Drug Administration expressed deep concerns about the use of MDMA to help treat post-traumatic stress disorder, companies working to…
Read More
Enveric Biosciences announced it has signed a nonbinding term sheet to out-license a class of novel psilocin prodrugs to MindBio Therapeutics, an agreement that could yield more than $66 million…
Read More
Enveric Biosciences signed a non-binding term sheet to out-license a class of novel psilocin products to MinBio Therapeutics for up to $66.5 million in milestone payments. Full Article >>
Read More
Enveric Biosciences reported it financial results on Wednesday for the first quarter of 2024 ended March 31, 2024. "We believe the first quarter of 2024 was a highly productive period…
Read More
